CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Nuvation Bio Inc.

NUVB
$2.08BMid Cap

Next catalyst

Phase 2March 2027

NUV-1511

Advanced Solid Tumor

Get an email about NUVB's next catalysts

Track Nuvation Bio (NUVB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

2 upcoming, 1 past

PDUFA
✅Approved

FDA PDUFA Date taletrectinib

Jan 4, 2027Taletrectinib

SNDA filing. Extracted from: Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Source
Phase 2Next

NUV-1511 Phase 2 Est. Readout

March 2027~NUV-1511466

Primary completion for NUV-1511 trial (NCT06334432) in Advanced Solid Tumor

Source

Market Overview

Stock performance and key metrics

NYSEPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Nuvation Bio Inc.'s drug pipeline?→

CatalystAlert tracks 5 drug candidates in Nuvation Bio Inc.'s (NUVB) pipeline across Phase 3, Phase 2. Its lead program is Taletrectinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Nuvation Bio Inc.'s next FDA catalyst?→

Nuvation Bio Inc.'s (NUVB) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track NUVB biotech catalysts?→

Add NUVB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nuvation Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply